GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Farmacosmo SpA (MIL:COSMO) » Definitions » EBIT

Farmacosmo SpA (MIL:COSMO) EBIT : €-2.31 Mil (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Farmacosmo SpA EBIT?

Farmacosmo SpA's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was €-0.61 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was €-2.31 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Farmacosmo SpA's annualized ROC % for the quarter that ended in Jun. 2024 was -9.63%. Farmacosmo SpA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -143.58%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Farmacosmo SpA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -8.29%.

Farmacosmo SpA EBIT Historical Data

The historical data trend for Farmacosmo SpA's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Farmacosmo SpA EBIT Chart

Farmacosmo SpA Annual Data
Trend Dec19 Dec20 Dec22 Dec23
EBIT
0.21 0.52 -1.61 -3.19

Farmacosmo SpA Semi-Annual Data
Dec19 Dec20 Jun21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial -0.14 -1.48 -1.53 -1.70 -0.61

Competitive Comparison of Farmacosmo SpA's EBIT

For the Pharmaceutical Retailers subindustry, Farmacosmo SpA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Farmacosmo SpA's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Farmacosmo SpA's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Farmacosmo SpA's EV-to-EBIT falls into.


Farmacosmo SpA EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-2.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Farmacosmo SpA  (MIL:COSMO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Farmacosmo SpA's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-1.716 * ( 1 - -3.75% )/( (16.721 + 20.251)/ 2 )
=-1.78035/18.486
=-9.63 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=36.4 - 19.916 - ( 5.065 - max(0, 20.347 - 20.11+5.065))
=16.721

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=33.675 - 13.238 - ( 4.653 - max(0, 19.971 - 20.157+4.653))
=20.251

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Farmacosmo SpA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.214/( ( (0.494 + max(-5.931, 0)) + (0.313 + max(0.884, 0)) )/ 2 )
=-1.214/( ( 0.494 + 1.197 )/ 2 )
=-1.214/0.8455
=-143.58 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.955 + 7.332 + 2.129) - (19.916 + 0 + 0.431)
=-5.931

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.475 + 8.39 + 1.711) - (13.238 + 0 + 0.454)
=0.884

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Farmacosmo SpA's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=-2.307/27.844
=-8.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Farmacosmo SpA EBIT Related Terms

Thank you for viewing the detailed overview of Farmacosmo SpA's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Farmacosmo SpA Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Farmacosmo SpA (MIL:COSMO) » Definitions » EBIT
Comparable Companies
MIL:TALEA WBA BSP:RADL3 HKSE:00241 TSE:3088 SAU:4164 SHSE:603939 TSE:3349 SHSE:600998 TSE:3391 JSE:CLS TSE:3141 TSE:9989 TSE:7649 SAU:4163 SHSE:603883 TSE:3549 SZSE:002727 HKSE:09885 TSE:3148
Traded in Other Exchanges
N/A
Address
Via Crispi, Number 51, Napoli, ITA, IT-80121
Website
https://www.farmacosmo.it
Farmacosmo SpA is a wellness e-commerce company active in the Health, Pharma, and Wellness industry, authorized by the Italian Ministry of Health to sell pharmaceutical products online. In particular, the company offers parapharmaceutical products, vitamins and food supplements, dietetic products, medical devices, cosmetic products, personal hygiene products, hair care products, dental care products, skincare products, perfumes, home and baby items.

Farmacosmo SpA Headlines

No Headlines